GH
GH.US Guardant Health Inc
- Market cap
- USD 20.5B
- P/E
- -
- P/B
- 55.67x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GH.US undervalued?
Graham numberThe Graham number of Guardant Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guardant Health Inc fundamental analysis
No fundamental analysis for Guardant Health Inc yet.
Guardant Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a …
Full company profileGuardant Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guardant Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.2M | 49.8M | 90.6M | 214M | 287M | 374M | 450M | 564M | 739M | 982M | 1.33B |
| Gross Profit | 3.13M | 18.2M | 47.4M | 144M | 194M | 251M | 293M | 337M | 449M | 633M | 869M |
| Operating Income | -43.8M | -76.6M | -92.9M | -82.4M | -255M | -411M | -544M | -565M | -444M | -437M | -511M |
| EBITDA | -39.4M | -75.3M | -75.8M | -57.1M | -225M | -360M | -615M | -433M | -390M | -374M | -430M |
| Net Income | -46.1M | -83.2M | -85.1M | -75.7M | -254M | -406M | -655M | -479M | -436M | -416M | -475M |
| EPS | -3.49 | -1.18 | -1.00 | -0.84 | -2.60 | -4.00 | -6.41 | -4.28 | -3.56 | -3.32 | -3.54 |
| Balance Sheet | |||||||||||
| Total Assets | 117M | 343M | 587M | 963M | 2.27B | 2.20B | 1.61B | 1.79B | 1.49B | 2.01B | 1.89B |
| Total Liabilities | 36.9M | 34.3M | 62.5M | 115M | 916M | 1.56B | 1.55B | 1.63B | 1.63B | 2.11B | 2.16B |
| Shareholders' Equity | 79.7M | 309M | 483M | 798M | 1.30B | 645M | 60.2M | 159M | -140M | -99.3M | -276M |
| Cash & Short-term Investments | 95.3M | 221M | 419M | 523M | 1.79B | 933M | 1.01B | 1.17B | 840M | 1.20B | 1.03B |
| Total Debt | 17.0M | 659K | 216K | 40.4M | 854M | 1.37B | 1.37B | 1.35B | 1.34B | 1.71B | 1.69B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -36.7M | -72.2M | -72.2M | -47.1M | -104M | -209M | -309M | -325M | -240M | -185M | -196M |
| Capital Expenditure | 1.77M | 8.98M | 20.2M | 21.3M | 54.1M | 75.0M | 77.5M | 20.5M | 35.1M | 48.3M | 41.1M |
| Free Cash Flow | -38.5M | -81.2M | -92.4M | -68.4M | -158M | -284M | -387M | -345M | -275M | -233M | -237M |
| Ratios | |||||||||||
| ROE | -57.9% | -27.0% | -17.6% | -9.5% | -19.5% | -62.9% | -1,087.7% | -302.1% | - | - | - |
| ROA | -39.6% | -24.3% | -14.5% | -7.9% | -11.2% | -18.4% | -40.7% | -26.8% | -29.4% | -20.7% | -25.2% |
| Net Profit Margin | -182.7% | -167.0% | -93.8% | -35.3% | -88.5% | -108.6% | -145.6% | -85.0% | -59.0% | -42.4% | -35.7% |
| Debt to Equity | 0.21x | 0.00x | 0.00x | 0.05x | 0.66x | 2.13x | 22.75x | 8.53x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guardant Health Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 17.9M | 0.18 | - |
| 2020 | USD 7.10M | 0.07 | - |
| 2019 | - | - | - |
| 2018 | USD 3.16M | 0.04 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Guardant Health Inc
- Insiders 3.95%
- Institutions 96.05%
- Public & others 0.00%
- Shares outstanding 135M
- Free float 131M
Top funds holding GH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.05M | 2.99% | +1.15% | Sep 2026 |
| Vanguard Small Cap Index | 2.87M | 2.12% | -1.00% | Sep 2026 |
| Franklin DynaTech Fund A | 1.80M | 1.33% | 0.00% | Sep 2026 |
| FullerThaler Behavioral Sm-Cp Gr R6 | 1.73M | 1.28% | +4.70% | Jun 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.60M | 1.18% | -4.02% | Sep 2026 |
| T. Rowe Price New Horizons | 1.59M | 1.18% | -5.26% | Sep 2026 |
| Eventide Gilead N | 1.27M | 0.94% | -21.18% | Jun 2026 |
| American Funds Growth Fd of Amer A | 1.11M | 0.82% | -11.80% | Sep 2026 |
| Vanguard Explorer Inv | 884K | 0.65% | +12.24% | Sep 2026 |
| Federated Hermes Kaufmann R | 880K | 0.65% | -3.98% | Sep 2026 |
| T. Rowe Price Mid-Cap Growth | 755K | 0.56% | +74.79% | Sep 2026 |
| American Funds IS® Growth 1 | 734K | 0.54% | -24.25% | Sep 2026 |
| T. Rowe Price Health Sciences | 732K | 0.54% | 0.00% | Sep 2026 |
| Lord Abbett Growth Leaders I | 678K | 0.50% | -1.33% | Aug 2026 |
| iShares Russell Mid-Cap Growth ETF | 644K | 0.48% | -0.07% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 640K | 0.47% | -8.57% | Jun 2026 |
| Columbia Small Cap Growth Inst | 639K | 0.47% | 0.00% | Sep 2026 |
| Invesco Discovery Mid Cap Growth Y | 635K | 0.47% | +3.22% | Sep 2026 |
| ARK Genomic Revolution ETF | 630K | 0.47% | +0.58% | Oct 2026 |
| Hood River Small-Cap Growth Instl | 623K | 0.46% | -6.70% | Jun 2026 |
Top institutions holding GH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 7.62M | 5.68% | -34.02% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 6.51M | 4.85% | -7.24% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.76M | 4.29% | +2.34% | Jun 2026 |
| FMR Inc | 5.49M | 4.09% | +33.34% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.45M | 4.06% | -6.72% | Jun 2026 |
| Amvescap Plc. | 4.43M | 3.30% | -10.45% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.78M | 2.81% | -14.88% | Jun 2026 |
| Two Sigma Investments LLC | 3.72M | 2.77% | -12.06% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 3.40M | 2.53% | -2.35% | Jun 2026 |
| Deep Track Capital, LP | 3.39M | 2.53% | +1.65% | Jun 2026 |
| Franklin Templeton Inc | 3.24M | 2.41% | -6.15% | Jun 2026 |
| Ameriprise Financial Inc | 3.15M | 2.35% | +122.70% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 2.63M | 1.96% | +3.09% | Jun 2026 |
| Geode Capital Management, LLC | 2.52M | 1.88% | -28.14% | Jun 2026 |
| Baillie Gifford & Co Limited. | 2.28M | 1.70% | -40.81% | Jun 2026 |
| State Street Corp | 2.26M | 1.69% | -21.53% | Jun 2026 |
| Federated Hermes Inc | 2.00M | 1.49% | +5.91% | Jun 2026 |
| Eventide Asset Management, LLC | 1.96M | 1.46% | -17.12% | Jun 2026 |
| Lord, Abbett & Co LLC | 1.81M | 1.35% | -4.51% | Jun 2026 |
| Jane Street Group LLC | 1.78M | 1.33% | +37,031.88% | Jun 2026 |
Guardant Health Inc company profile
- Company name
- Guardant Health Inc
- Ticker
- GH.US
- Exchange
- USA Stocks
- Listed since
- Oct 4, 2018
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 2,490
- Fiscal year end
- December
- Address
- 3100 Hanover Street, Palo Alto, CA, United States, 94304
- Phone
- 855 698 8887
- Website
- guardanthealth.com
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Guardant Health Inc management
10- Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman · born 1979
- Dr. AmirAli Talasaz Ph.D.Co-Founder, Co-CEO & Director · born 1979
- Mr. Michael BellChief Financial Officer · born 1969
- Dr. Darya ChudovaChief Technology Officer · born 1974
- Mr. John G. Saia J.D.Chief Legal Officer & Corporate Secretary · born 1973
- Mr. Andy AmentSenior Vice President of Operations
- Mr. Robert A. ParksSenior VP, Principal Accounting Officer & Chief Accounting Officer · born 1972
- Mr. Kumud KaliaChief Information Officer · born 1966
- Zarak KhurshidVice President of Investor Relations
- Ms. Gulshan Shaver J.D.Senior VP of Legal Affairs & Chief Compliance Officer